SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (12158)2/10/2019 1:55:06 PM
From: Miljenko Zuanic  Read Replies (1) of 12215
 
Autologous TIL therapy is already part of many trials: clinicaltrials.gov

Main hardness is toxicity. So they say.
If TILs are sufficiently SPECIFIC (no systemic toxicity), have no idea for off target toxicity (associated v specific),....are you suggesting (from then manuscript, didn't read...simple because can not understand 1/10 of it) that (from cancer tissue samples) isolated TIL that recognized/active toward TP53 gene mutation (neoantigen derived from mutated p53) will work for almost any cancer harboring that mutation? Metastatic cancer, sample for primary tumor?

I still do not understand simple biology explanation of the standard immune response (where is and where it is not), so to understand immune response toward cancer cells is way too harder.

Thanks.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News